You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 25 Next »




Project Scope
Development and delivery of education relevant to clinical trial safety analyses, with a focus on Phase 2-3.
Problem Statment 

Planning and interpreting clinical trial safety analyses demands scientific expertise that is often missing in educational curricula. The Safety Analytics field is dynamic and evolving, requiring continual learning. All the roles (for example, medical, statistics, writers) that collaborate on ongoing safety reviews, clinical study reports and integrated submission documents can improve their planning, content, execution, and communication of clinical trial safety analyses

Problem Impact

Improving Safety Analytics Education will lead to better content, implementation, and understanding of clinical trial safety analyses. Additionally, when stakeholders are educated, less time is needed for aligning on analysis plans and data interpretations.

Although not a formal project yet, members of the Safety Analytics Education project team have been active in delivering and promoting educational content for a while:

  • Leading safety analytics workshops at the PHUSE CSS
  • Presenting at the Duke Margolis-FDA workshop on advancing premarket safety analytics
  • Partnering with the PHUSE Education team to create and maintain a Safety Analytics Education website
  • Hosting a webinar series on interdisciplinary safety evaluation for decision-making

Creating an education project team will provide a dedicated channel for future efforts and enhance the standing of PHUSE in the safety analytics space.

Project Leads

Emails

Christopher Smith, FDA

Christopher.Smith2@fda.hhs.gov

William Palo, AbbVie

william.palo@abbvie.com

Nicola Newton, PHUSE Project Assistant

nicky@phuse.global

CURRENT STATUS Q1 2024

  • Calling for Volunteers 

Safety Analytics Webinar Series 2023: 

Date      

Title  

Speakers

Recording

15 June

Scientific Evaluation of Safety Data and Aggregate Safety Assessment Planning for IND Safety ReportingGreg Ball, ASAP Process Consulting, Jacqueline Corrigan-Curay, FDA, Barbara Hendrickson, University of Chicago & Brian Waterhouse, MerckRecording
13 JulyOverall Safety Assessment – Standard Safety Tables and FiguresJim Buchanan, Covilance), Mary Nilsson, Eli Lilly & Veronica Pei, FDARecording
14 September     

Overall Safety Assessment – AE Groupings for Assessment of Safety Topics of Interest

Greg Ball, ASAP Process Consulting, Mac Gordon, Johnson & Johnson), Peg Fletcher, MedAssessment & Scott Proestel, FDA

Recording 
4 October

Overall Safety Assessment – Interactive Safety Graphics for Regulatory Decision-Making

Jeremy Wildfire, Gilead, Steve Mallett, Veramed & Mat Soukup, FDA/CDER

Recording
16 November

Interdisciplinary Safety Evaluation for Learning and Decision-Making: Education for Executives              

Greg Ball, ASAP Process Consulting, Jacqueline Corrigan-Curay, FDA, Barbara Hendrickson, University of Chicago & Sheila Mahoney-Jewels, LifeSciHub 

Recording
  • No labels